RU2017116973A - Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса - Google Patents
Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса Download PDFInfo
- Publication number
- RU2017116973A RU2017116973A RU2017116973A RU2017116973A RU2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A RU 2017116973 A RU2017116973 A RU 2017116973A
- Authority
- RU
- Russia
- Prior art keywords
- heart failure
- pharmaceutical preparation
- mammal
- neuregulin
- composition
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title claims 6
- 102000014413 Neuregulin Human genes 0.000 title claims 6
- 108050003475 Neuregulin Proteins 0.000 title claims 6
- 239000000203 mixture Substances 0.000 title claims 2
- 230000002265 prevention Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 7
- 241000124008 Mammalia Species 0.000 claims 6
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 claims 2
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 claims 2
- 101000653754 Rattus norvegicus Sphingosine 1-phosphate receptor 5 Proteins 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (10)
1. Применение нейрегулина при приготовлении лекарственного средства для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса у млекопитающего.
2. Применение по п.1, где нейрегулин представляет собой NRG-1.
3. Применение по п.1, где нейрегулин содержит последовательность аминокислот SEQ ID NO: 1.
4. Применение по п.1, где млекопитающее представляет собой человека.
5. Фармацевтический препарат для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса у млекопитающего, который содержит эффективное количество NRG.
6. Фармацевтический препарат по п.5, где нейрегулин представляет собой NRG-1.
7. Фармацевтический препарат по п.5, где нейрегулин содержит последовательность аминокислот SEQ ID NO: 1.
8. Фармацевтический препарат по п.5, где млекопитающее представляет собой человека.
9. Композиция для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса у млекопитающего, которая содержит фармацевтический препарат по п.5 и другое лекарственное средство (лекарственные средства) для лечения сердечной недостаточности с сохраненной фракцией выброса.
10. Набор, используемый для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса у млекопитающего, который содержит фармацевтический препарат по п.5 и инструкции относительно того как использовать этот фармацевтический препарат.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410550212.7A CN105561298A (zh) | 2014-10-17 | 2014-10-17 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
| CN201410550212.7 | 2014-10-17 | ||
| PCT/CN2015/091459 WO2016058493A1 (zh) | 2014-10-17 | 2015-10-08 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017116973A true RU2017116973A (ru) | 2018-11-19 |
| RU2017116973A3 RU2017116973A3 (ru) | 2019-05-06 |
Family
ID=55746124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017116973A RU2017116973A (ru) | 2014-10-17 | 2015-10-08 | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10561709B2 (ru) |
| EP (2) | EP3207940B1 (ru) |
| JP (3) | JP2017532343A (ru) |
| KR (2) | KR102603711B1 (ru) |
| CN (3) | CN105561298A (ru) |
| AU (2) | AU2015333335B2 (ru) |
| CA (1) | CA2963322A1 (ru) |
| ES (1) | ES2924395T3 (ru) |
| RU (1) | RU2017116973A (ru) |
| WO (1) | WO2016058493A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2530526T3 (es) | 2005-12-30 | 2015-03-03 | Zensun Shanghai Science And Technology Ltd | Liberación extendida de neurregulina para mejorar la función cardíaca |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| WO2014056121A1 (en) | 2012-10-08 | 2014-04-17 | Zensun (Shanghai) Science & Technology Limited | Compositions and methods for treating heart failure in diabetic patients |
| AU2014270882B2 (en) | 2013-05-22 | 2019-03-14 | Zensun (Shanghai) Science & Technology, Co. Ltd. | Extended release of neuregulin for treating heart failure |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
| CN113166218A (zh) | 2018-04-11 | 2021-07-23 | 信立泰生物医药公司 | 人神经调节蛋白-1(nrg-1)重组融合蛋白组合物和其使用方法 |
| CN111407881A (zh) * | 2019-01-07 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物 |
| AR121035A1 (es) * | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
| CN113289002A (zh) * | 2020-02-24 | 2021-08-24 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物 |
| CN117797243A (zh) * | 2022-09-30 | 2024-04-02 | 上海泽生科技开发股份有限公司 | 神经调节蛋白及其应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989001489A1 (en) | 1987-08-10 | 1989-02-23 | Commonwealth Scientific And Industrial Research Or | Control of angiogenesis and compositions and methods therefor |
| US7115554B1 (en) | 1993-05-06 | 2006-10-03 | Acorda Therapeutics, Inc. | Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III |
| US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
| US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
| US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
| US6750196B1 (en) | 1995-03-27 | 2004-06-15 | Acorda Therapeutics | Methods of treating disorders of the eye |
| US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
| DE69840699D1 (de) | 1997-02-10 | 2009-05-14 | Genentech Inc | Heregulin varianten |
| WO1999018976A1 (en) | 1997-10-14 | 1999-04-22 | Cambridge Neuroscience, Inc. | Therapeutic methods comprising use of a neuregulin |
| US6054261A (en) | 1998-05-20 | 2000-04-25 | Q-Pharma, Inc. | Coenzyme Q10 compositions for organ protection during perfusion |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| US6635249B1 (en) * | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
| CN1138785C (zh) | 1999-06-04 | 2004-02-18 | 周明东 | 生长因子神经调节蛋白及其类似物的新应用 |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| WO2001064877A2 (en) | 2000-02-28 | 2001-09-07 | Decode Genetics Ehf | Human schizophrenia gene |
| EP2357004B1 (en) | 2000-05-23 | 2016-10-12 | CeNeS Pharmaceuticals, Inc. | NRG-2 nucleic acid molecules, polypeptides and diagnostic and therapeutical methods |
| WO2002024889A2 (en) | 2000-09-12 | 2002-03-28 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Optimized cardiac contraction through differential phosphorylation of myosin |
| US6482624B2 (en) | 2000-11-14 | 2002-11-19 | Pe Corporation (Ny) | Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| RU2180843C1 (ru) | 2001-02-19 | 2002-03-27 | Новокузнецкий государственный институт усовершенствования врачей | Способ профилактики повторного инфаркта миокарда |
| AU2002304965A1 (en) | 2002-05-24 | 2003-12-12 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
| CN1498656A (zh) * | 2002-11-08 | 2004-05-26 | 上海泽生科技开发有限公司 | 神经调节蛋白用于心肌梗死治疗的方法和组合物 |
| US20060275770A1 (en) | 2002-11-27 | 2006-12-07 | Daniel Bednarik | Heart failure gene determination and therapeutic screening |
| US20050112128A1 (en) | 2003-05-21 | 2005-05-26 | Myogen, Inc. And Board Of Regents, The University Of Texas System | Inhibition of protein kinase c-mu (PKD) as a treatment for cardiac hypertrophy and heart failure |
| CN1715926B (zh) | 2004-07-02 | 2011-08-17 | 上海泽生科技开发有限公司 | 神经调节蛋白突变体的应用 |
| WO2006108208A1 (en) | 2004-10-14 | 2006-10-19 | Adventures Plus Pty Ltd | A method for the treatment of gastrointestinal and other disorders with an admixture of vitamins and minerals |
| US20060160062A1 (en) | 2005-01-14 | 2006-07-20 | Young Lindon H | Perfusion and/or preservation solution for organs |
| US20070141548A1 (en) | 2005-03-11 | 2007-06-21 | Jorg Kohl | Organ transplant solutions and method for transplanting organs |
| CN100361709C (zh) | 2005-08-30 | 2008-01-16 | 山东省生物药物研究院 | 一种对生命活性物质有保护作用的糖类组合 |
| CN1768859A (zh) | 2005-10-24 | 2006-05-10 | 天津大学 | 基于醛基的微粒表面多重生物功能因子组装方法 |
| US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
| CN101394861A (zh) * | 2005-12-30 | 2009-03-25 | 上海泽生科技开发有限公司 | 纽兰格林持续给药能改善心脏功能 |
| ES2530526T3 (es) | 2005-12-30 | 2015-03-03 | Zensun Shanghai Science And Technology Ltd | Liberación extendida de neurregulina para mejorar la función cardíaca |
| US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
| ES2548009T3 (es) | 2007-01-25 | 2015-10-13 | F. Hoffmann-La Roche Ag | Uso de IGFBP-7 en la evaluación de la insuficiencia cardíaca |
| CN101310766B (zh) | 2007-05-25 | 2014-04-16 | 上海泽生科技开发有限公司 | 神经调节蛋白的新用途 |
| CN101310779A (zh) | 2007-05-25 | 2008-11-26 | 上海泽生科技开发有限公司 | 包含神经调节蛋白的装置及药物制剂 |
| US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
| ES2664394T3 (es) * | 2008-07-17 | 2018-04-19 | Acorda Therapeutics, Inc. | Dosificación terapéutica de una neuregulina o de una subsecuencia de la misma para el tratamiento o la profilaxis de la insuficiencia cardiaca |
| US8609620B2 (en) | 2008-11-28 | 2013-12-17 | Zensun (Shanghai) Science & Technology Ltd. | Neuregulin peptides and their use |
| WO2010060266A1 (en) | 2008-11-28 | 2010-06-03 | Zensun (Shanghai) Science & Technology Limited | Neuregulin and cardiac stem cells |
| WO2010142141A1 (en) | 2009-06-09 | 2010-12-16 | Zensun (Shanghai) Science & Technology Limited | Neuregulin based methods for treating heart failure |
| JP2013503110A (ja) | 2009-06-09 | 2013-01-31 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド | ニューレグリンに基づく心不全の治療方法 |
| JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． | ニューレグリンに基づく心不全の治療方法 |
| CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
| US20130045937A1 (en) | 2010-03-10 | 2013-02-21 | Cempra Pharmaceuticals, Inc. | Parenteral formulations of macrolide antibiotics |
| US9029328B2 (en) * | 2010-03-24 | 2015-05-12 | The Brigham And Women's Hospital, Inc. | Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands |
| CN103327986B (zh) | 2010-07-22 | 2018-05-25 | 雷文制药有限公司 | 包含使用磁偶极子稳定化溶液的治疗或改善疾病并增强表现的方法 |
| WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun （Shanghai）Science & Technology Limited | Compositions and methods for treating heart failure |
| CA2868996A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2014056121A1 (en) | 2012-10-08 | 2014-04-17 | Zensun (Shanghai) Science & Technology Limited | Compositions and methods for treating heart failure in diabetic patients |
| US20160129084A1 (en) * | 2013-03-06 | 2016-05-12 | Acorda Therapeutics, Inc. | Therapeutic Dosing of a Neuregulin or a Fragment Thereof for Treatment or Prophylaxis of Heart Failure |
| AU2014270882B2 (en) | 2013-05-22 | 2019-03-14 | Zensun (Shanghai) Science & Technology, Co. Ltd. | Extended release of neuregulin for treating heart failure |
| CN104758300A (zh) | 2014-01-02 | 2015-07-08 | 上海泽生科技开发有限公司 | 维生素d及其组合物的抗菌用途 |
| CN104758922A (zh) | 2014-01-03 | 2015-07-08 | 上海泽生科技开发有限公司 | 纽兰格林制剂的配方 |
| CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
-
2014
- 2014-10-17 CN CN201410550212.7A patent/CN105561298A/zh active Pending
- 2014-10-17 CN CN202010283482.1A patent/CN111407882A/zh active Pending
-
2015
- 2015-10-08 EP EP15850529.7A patent/EP3207940B1/en active Active
- 2015-10-08 JP JP2017520447A patent/JP2017532343A/ja active Pending
- 2015-10-08 US US15/518,730 patent/US10561709B2/en active Active
- 2015-10-08 ES ES15850529T patent/ES2924395T3/es active Active
- 2015-10-08 KR KR1020177010326A patent/KR102603711B1/ko active IP Right Grant
- 2015-10-08 EP EP22174662.1A patent/EP4112068A1/en active Pending
- 2015-10-08 RU RU2017116973A patent/RU2017116973A/ru not_active Application Discontinuation
- 2015-10-08 AU AU2015333335A patent/AU2015333335B2/en active Active
- 2015-10-08 CA CA2963322A patent/CA2963322A1/en not_active Abandoned
- 2015-10-08 CN CN201580054201.2A patent/CN108064164A/zh active Pending
- 2015-10-08 WO PCT/CN2015/091459 patent/WO2016058493A1/zh active Application Filing
- 2015-10-08 KR KR1020237039263A patent/KR20230159650A/ko not_active Application Discontinuation
-
2019
- 2019-12-13 US US16/714,397 patent/US20200368317A1/en not_active Abandoned
-
2020
- 2020-08-21 JP JP2020139931A patent/JP2020193217A/ja active Pending
-
2021
- 2021-10-29 AU AU2021258063A patent/AU2021258063A1/en active Pending
- 2021-12-21 US US17/558,451 patent/US20220354928A1/en active Pending
-
2022
- 2022-07-06 JP JP2022108771A patent/JP2022153417A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200368317A1 (en) | 2020-11-26 |
| RU2017116973A3 (ru) | 2019-05-06 |
| CN108064164A (zh) | 2018-05-22 |
| WO2016058493A1 (zh) | 2016-04-21 |
| KR102603711B1 (ko) | 2023-11-20 |
| CA2963322A1 (en) | 2016-04-21 |
| AU2015333335B2 (en) | 2021-08-05 |
| KR20230159650A (ko) | 2023-11-21 |
| JP2022153417A (ja) | 2022-10-12 |
| JP2017532343A (ja) | 2017-11-02 |
| CN111407882A (zh) | 2020-07-14 |
| AU2021258063A1 (en) | 2021-11-25 |
| EP3207940A1 (en) | 2017-08-23 |
| JP2020193217A (ja) | 2020-12-03 |
| US10561709B2 (en) | 2020-02-18 |
| EP3207940B1 (en) | 2022-06-01 |
| ES2924395T3 (es) | 2022-10-06 |
| US20170232068A1 (en) | 2017-08-17 |
| EP3207940A4 (en) | 2018-06-06 |
| CN105561298A (zh) | 2016-05-11 |
| KR20170066440A (ko) | 2017-06-14 |
| EP4112068A1 (en) | 2023-01-04 |
| US20220354928A1 (en) | 2022-11-10 |
| AU2015333335A1 (en) | 2017-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017116973A (ru) | Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса | |
| JP2017532343A5 (ru) | ||
| MX2018014573A (es) | Vacuna contra el virus del zika. | |
| BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
| MX2019012884A (es) | Terapia de combinacion. | |
| ES2682670T3 (es) | Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas | |
| UA117096C2 (uk) | Поліпептид, що зв'язується з c5 комплементу людини | |
| RU2017113775A (ru) | Применение нейрегулина в профилактике, лечении или отсрочке развития желудочковой аритмии и его композиция | |
| WO2011112867A8 (en) | The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas | |
| JP2018509388A5 (ru) | ||
| WO2015187998A3 (en) | Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy | |
| WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
| EP4279128A3 (en) | Novel antibody binding to tfpi and composition comprising the same | |
| WO2016005328A3 (en) | IMMUNOGENIC PRODUCTS BASED ON MUTEIN AMYLOID ß (Aß) AMINO ACID SEQUENCES AND USES THEREOF | |
| CA3010568A1 (en) | Oromucosal nanofiber carriers for therapeutic treatment | |
| RU2017128296A (ru) | Композиция для лечения бесплодия | |
| WO2016040169A3 (en) | Mucolytic agents for use in tretaing pulmonary sarcoidosis | |
| CA3010788A1 (en) | Methods of administering vasopressors | |
| AR095076A1 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| WO2015168488A3 (en) | Islet amyloid polypeptides with improved solubility | |
| EA201691498A1 (ru) | Новая мишень для лечения и профилактики диабета | |
| EP4361634A3 (en) | Methods for treating and monitoring the status of cancer | |
| RU2017126212A (ru) | Композиция | |
| JP2016515123A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HZ9A | Changing address for correspondence with an applicant | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200805 |